11 recruiting. 11 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 11 | Recruiting 11 |
| Phase 2 | 3 | Recruiting 3 |
Follow Immunotherapy: new trials by email Literature Review of Immunotherapy trials Research Report on Immunotherapy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Controlled Cold Exposure Combined With PD-1/PD-L1 Immunotherapy in Solid Tumors (NIVALIS) Controlled Cold Exposure, Investigator-Selected Standard PD-1/PD-L1 Inhibitor-Based Therapy - Solid Tumors, Solid Malignancies | Phase 1 | Recruiting | West China Hospital | 24 | 2026-04-20 | 2026-05-28 |
| A Study of ABT-301 Plus Tislelizumab With Bevacizumab in pMMR/Non-MSI-H Locally Advanced or mCRC ABT-301, Tislelizumab, Bevacizumab (Avastin) - Colorectal Cancer (Diagnosis), Colorectal Cancer Metastatic | Phase 1 / Phase 2 | Recruiting | Anbogen Therapeutics, Inc. | 66 | 2025-11-01 | 2025-11-24 |
| VSV-02 Compassionate Use in Advanced Solid Tumors VSV-02 Injection - Advanced Solid Tumor, Melanoma | Phase 1 | Recruiting | The First Affiliated Hospital of Xinxiang Medical College | 6 | 2025-09-22 | 2025-12-03 |
| Hypofractionated Radiotherapy Combined With Immunochemotherapy for Conversion Treatment of Gastroesophageal Junction Adenocarcinoma hypofractionated radiotherapy, SOX Chemotherapy, PD-1 inhibitor - Gastroesophageal Junction Adenocarcinoma, Hypofractionated Radiotherapy | Phase 1 / Phase 2 | Recruiting | West China Hospital | 88 | 2025-09-15 | 2025-11-28 |
| A Phase I Trial of Tumor-Associated Lymph Node T-Cell Injection With Advanced Malignant Solid Tumors Tumor Associated Lymph node T cell, Serplulimab Injection - Tumor Associated Lymph Node T Cell, Advanced Solid Tumor | Phase 1 | Recruiting | Guangzhou FineImmune Biotechnology Co., LTD. | 32 | 2025-02-13 | 2025-03-26 |
| Phase I Clinical Study of Tumor-associated Lymph Node T Cell Therapy for Advanced Solid Tumors Tumor Associated Lymph node T cell, cyclophosphamide, IL-2 - Advanced Solid Tumor, Tumor Associated Lymph Node T Cell | Phase 1 | Recruiting | Guangzhou FineImmune Biotechnology Co., LTD. | 23 | 2023-06-06 | 2024-12-03 |
| Precision Therapy for Solid Tumors: Synergistic CDK4/6 Inhibition and Anti-VEGF Targeting LncRNA SNP, Palbociclib 125mg, Bevacizumab - Cancer, Solid Tumor | Phase 1 | Recruiting | Lebanese University | 50 | 2023-02-15 | 2024-03-12 |
| Clinical Study of PSMA-targeted CAR-T Cells in the Treatment of Castration-resistant Prostate Cancer CAR-T cell immunotherapy - Immunotherapy | Phase 1 | Recruiting | The Affiliated Hospital of Xuzhou Medical University | 20 | 2022-12-01 | 2022-04-29 |
| Concurrent Chemoradiotherapy Followed by PD-1 Inhibitor in Advanced Cervical Cancer Albumin-Bound Paclitaxel, cisplatin, Sintilimab - Locally Advanced Cervical Carcinoma, Concurrent Chemoradiotherapy | Phase 1 / Phase 2 | Recruiting | RenJi Hospital | 20 | 2022-01-01 | 2024-04-30 |
| GPC3-CAR-T Cells for Immunotherapy of Cancer With GPC3 Expression GPC3 and/or TGFβ targeting CAR-T cells - Hepatocellular Carcinoma, Immunotherapy | Phase 1 | Recruiting | Second Affiliated Hospital of Guangzhou Medical University | 30 | 2017-07-01 | 2024-06-25 |
| GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR-T Cells Against Cancers CAR-T cells targeting GPC3, Mesothelin, Claudin18.2, GUCY2C, B7-H3, PSCA, PSMA, MUC1, TGFβ, HER2, Lewis-Y, AXL, or EGFR - Lung Cancer, Cancer | Phase 1 | Recruiting | Second Affiliated Hospital of Guangzhou Medical University | 30 | 2017-07-01 | 2024-06-25 |
Lung Neoplasms (3) · Breast Neoplasms (2) · Colorectal Neoplasms (2) · Drug-Related Side Effects and Adverse Reactions (2) · Neoplasms (2) · Carcinoma, Hepatocellular (1) · Disease (1) · Inflammation (1) · Melanoma (1) · Ovarian Neoplasms (1) · Simpson-Golabi-Behmel syndrome (1)
Neoplasms by Site (5) · Digestive System Diseases (3) · Digestive System Neoplasms (3) · Lung Diseases (3) · Neoplasms (3) · Respiratory Tract Diseases (3) · Respiratory Tract Neoplasms (3) · Thoracic Neoplasms (3) · Breast Diseases (2) · Chemically-Induced Disorders (2) · Colonic Diseases (2) · Gastrointestinal Diseases (2) · Gastrointestinal Neoplasms (2) · Intestinal Diseases (2) · Intestinal Neoplasms (2)
Bevacizumab (2) · 3-(1-benzenesulfonyl-2,3-dihydro-1H-indol-5-yl)-N-hydroxyacrylamide (1) · Albumin-Bound Paclitaxel (1) · Cisplatin (1) · Cyclophosphamide (1) · Guanylate Cyclase (1) · Immune Checkpoint Inhibitors (1) · Immunotherapy, Adoptive (1) · Interleukin-2 (1) · Mesothelin (1) · PSCA protein, human (1) · Radiation (1) · Radiation Dose Hypofractionation (1) · palbociclib (1) · sintilimab (1)
Guangzhou FineImmune Biotechnology Co., LTD. (2) · Second Affiliated Hospital of Guangzhou Medical University (2) · West China Hospital (2) · Anbogen Therapeutics, Inc. (1) · Lebanese University (1) · RenJi Hospital (1) · The Affiliated Hospital of Xuzhou Medical University (1) · The First Affiliated Hospital of Xinxiang Medical College (1)
China (9) · Australia (1) · Lebanon (1) · Taiwan (1)
Zhenfeng Zhang, MD,PhD (2) · Hailong Li, M.D/Ph.D (1) · Junnian Zheng, M.D/Ph.D (1) · LiuZhong Yang, master (1) · Nehman Makdissy, Professor (1) · Qing Zhang, Ph.D (1)
PMID 21075954, PMID 23256743, PMID 25279468, PMID 25358763, PMID 27324746, PMID 28123387, PMID 28405515, PMID 28541315, PMID 29048935, PMID 31085757, PMID 31281894, PMID 31862474, PMID 32097050, PMID 34325726, PMID 42568612